Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer

J. C. Waldrep, A. Berlinski, Rajiv Dhand

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Different approaches have been employed for in vitro assessment of the aerosol particle size generated by inhalation devices. In this study, aerosols from the Omron MicroAir vibrating mesh (VM) nebulizer were measured by cascade impaction (CI) using the MSP Next Generation Pharmaceutical Impactor (NGI), the ThermoAndersen Cascade Impactor (ACI), and by time-of-flight (TOF) analysis with the TSI 3321 Aerodynamic Particle Sizer Spectrometer (APS). The VM nebulizer was evaluated with sodium fluoride (NaF; 2.5%) and with generic albuterol (0.083%). Aerosol particle size (MMAD), respirable fractions (RF < 5 μm), and fine particle fractions (FPF < 3.3 μm) were determined with each method at room temperature (RT) and 4°C using 50% average relative humidity. By NGI at either RT or 4°C, aerosol particle sizes were similar for both NaF and albuterol (4.3-4.5 μm MMAD) with 55-61% RF and 27-43% FPF. With ACI, the distribution of particles at RT was similar except at the extremes of the dispersion and the MMAD was smaller (3.3 μm MMAD; p = 0.03). At 4°C, particle sizes determined by ACI results were similar to the NGI (MMAD 4.1 μm; p > 0.05). TOF analysis by APS with albuterol gave significantly larger calculated MMAD (cMMAD) than either CI method (7.2 μm; p < 0.001). TOF measurements of nebulized albuterol at RT and 4°C were equivalent. In summary, the results of VM nebulized NaF and albuterol were more consistent and generally equivalent when determined by NGI (at RT and 4°C) and ACI analysis (at 4°C). In contrast, aerosol particle sizes measured by TOF in the APS at both RT and 4°C were larger than results obtained by CI. Differences in aerosol particle distribution obtained by different analysis methods should be considered while evaluating the in vitro performance of VM nebulizers.

Original languageEnglish (US)
Pages (from-to)310-319
Number of pages10
JournalJournal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung
Volume20
Issue number3
DOIs
StatePublished - Sep 28 2007

Fingerprint

Nebulizers and Vaporizers
Aerosols
Albuterol
Particle Size
Sodium Fluoride
Pharmaceutical Preparations
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)

Cite this

Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer. / Waldrep, J. C.; Berlinski, A.; Dhand, Rajiv.

In: Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung, Vol. 20, No. 3, 28.09.2007, p. 310-319.

Research output: Contribution to journalArticle

@article{06972b3e94a04f31a4e92e22087cb314,
title = "Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer",
abstract = "Different approaches have been employed for in vitro assessment of the aerosol particle size generated by inhalation devices. In this study, aerosols from the Omron MicroAir vibrating mesh (VM) nebulizer were measured by cascade impaction (CI) using the MSP Next Generation Pharmaceutical Impactor (NGI), the ThermoAndersen Cascade Impactor (ACI), and by time-of-flight (TOF) analysis with the TSI 3321 Aerodynamic Particle Sizer Spectrometer (APS). The VM nebulizer was evaluated with sodium fluoride (NaF; 2.5{\%}) and with generic albuterol (0.083{\%}). Aerosol particle size (MMAD), respirable fractions (RF < 5 μm), and fine particle fractions (FPF < 3.3 μm) were determined with each method at room temperature (RT) and 4°C using 50{\%} average relative humidity. By NGI at either RT or 4°C, aerosol particle sizes were similar for both NaF and albuterol (4.3-4.5 μm MMAD) with 55-61{\%} RF and 27-43{\%} FPF. With ACI, the distribution of particles at RT was similar except at the extremes of the dispersion and the MMAD was smaller (3.3 μm MMAD; p = 0.03). At 4°C, particle sizes determined by ACI results were similar to the NGI (MMAD 4.1 μm; p > 0.05). TOF analysis by APS with albuterol gave significantly larger calculated MMAD (cMMAD) than either CI method (7.2 μm; p < 0.001). TOF measurements of nebulized albuterol at RT and 4°C were equivalent. In summary, the results of VM nebulized NaF and albuterol were more consistent and generally equivalent when determined by NGI (at RT and 4°C) and ACI analysis (at 4°C). In contrast, aerosol particle sizes measured by TOF in the APS at both RT and 4°C were larger than results obtained by CI. Differences in aerosol particle distribution obtained by different analysis methods should be considered while evaluating the in vitro performance of VM nebulizers.",
author = "Waldrep, {J. C.} and A. Berlinski and Rajiv Dhand",
year = "2007",
month = "9",
day = "28",
doi = "10.1089/jam.2007.0538",
language = "English (US)",
volume = "20",
pages = "310--319",
journal = "Journal of Aerosol Medicine and Pulmonary Drug Delivery",
issn = "1941-2711",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer

AU - Waldrep, J. C.

AU - Berlinski, A.

AU - Dhand, Rajiv

PY - 2007/9/28

Y1 - 2007/9/28

N2 - Different approaches have been employed for in vitro assessment of the aerosol particle size generated by inhalation devices. In this study, aerosols from the Omron MicroAir vibrating mesh (VM) nebulizer were measured by cascade impaction (CI) using the MSP Next Generation Pharmaceutical Impactor (NGI), the ThermoAndersen Cascade Impactor (ACI), and by time-of-flight (TOF) analysis with the TSI 3321 Aerodynamic Particle Sizer Spectrometer (APS). The VM nebulizer was evaluated with sodium fluoride (NaF; 2.5%) and with generic albuterol (0.083%). Aerosol particle size (MMAD), respirable fractions (RF < 5 μm), and fine particle fractions (FPF < 3.3 μm) were determined with each method at room temperature (RT) and 4°C using 50% average relative humidity. By NGI at either RT or 4°C, aerosol particle sizes were similar for both NaF and albuterol (4.3-4.5 μm MMAD) with 55-61% RF and 27-43% FPF. With ACI, the distribution of particles at RT was similar except at the extremes of the dispersion and the MMAD was smaller (3.3 μm MMAD; p = 0.03). At 4°C, particle sizes determined by ACI results were similar to the NGI (MMAD 4.1 μm; p > 0.05). TOF analysis by APS with albuterol gave significantly larger calculated MMAD (cMMAD) than either CI method (7.2 μm; p < 0.001). TOF measurements of nebulized albuterol at RT and 4°C were equivalent. In summary, the results of VM nebulized NaF and albuterol were more consistent and generally equivalent when determined by NGI (at RT and 4°C) and ACI analysis (at 4°C). In contrast, aerosol particle sizes measured by TOF in the APS at both RT and 4°C were larger than results obtained by CI. Differences in aerosol particle distribution obtained by different analysis methods should be considered while evaluating the in vitro performance of VM nebulizers.

AB - Different approaches have been employed for in vitro assessment of the aerosol particle size generated by inhalation devices. In this study, aerosols from the Omron MicroAir vibrating mesh (VM) nebulizer were measured by cascade impaction (CI) using the MSP Next Generation Pharmaceutical Impactor (NGI), the ThermoAndersen Cascade Impactor (ACI), and by time-of-flight (TOF) analysis with the TSI 3321 Aerodynamic Particle Sizer Spectrometer (APS). The VM nebulizer was evaluated with sodium fluoride (NaF; 2.5%) and with generic albuterol (0.083%). Aerosol particle size (MMAD), respirable fractions (RF < 5 μm), and fine particle fractions (FPF < 3.3 μm) were determined with each method at room temperature (RT) and 4°C using 50% average relative humidity. By NGI at either RT or 4°C, aerosol particle sizes were similar for both NaF and albuterol (4.3-4.5 μm MMAD) with 55-61% RF and 27-43% FPF. With ACI, the distribution of particles at RT was similar except at the extremes of the dispersion and the MMAD was smaller (3.3 μm MMAD; p = 0.03). At 4°C, particle sizes determined by ACI results were similar to the NGI (MMAD 4.1 μm; p > 0.05). TOF analysis by APS with albuterol gave significantly larger calculated MMAD (cMMAD) than either CI method (7.2 μm; p < 0.001). TOF measurements of nebulized albuterol at RT and 4°C were equivalent. In summary, the results of VM nebulized NaF and albuterol were more consistent and generally equivalent when determined by NGI (at RT and 4°C) and ACI analysis (at 4°C). In contrast, aerosol particle sizes measured by TOF in the APS at both RT and 4°C were larger than results obtained by CI. Differences in aerosol particle distribution obtained by different analysis methods should be considered while evaluating the in vitro performance of VM nebulizers.

UR - http://www.scopus.com/inward/record.url?scp=34648828033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34648828033&partnerID=8YFLogxK

U2 - 10.1089/jam.2007.0538

DO - 10.1089/jam.2007.0538

M3 - Article

VL - 20

SP - 310

EP - 319

JO - Journal of Aerosol Medicine and Pulmonary Drug Delivery

JF - Journal of Aerosol Medicine and Pulmonary Drug Delivery

SN - 1941-2711

IS - 3

ER -